Virtual Library

Start Your Search

Yoshinori Kodama

Author of

  • +

    P1.14 - Thymoma/Other Thoracic Malignancies (Not CME Accredited Session) (ID 946)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/24/2018, 16:45 - 18:00, Exhibit Hall
    • +

      P1.14-11 - The Expression Pattern of Programmed Death-Ligand 1 According to the Pathological Type of Malignant Thymic Epithelial Tumors (ID 12665)

      16:45 - 18:00  |  Author(s): Yoshinori Kodama

      • Abstract
      • Slides


      Malignant thymic epithelial tumors (TETs) have pathological types ranging from low-grade to high-grade malignancy, while the pattern of PD-L1 expression remains unclear. We investigated PD-L1 expression in TETs and verified the pattern of expression associated with the pathological type.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      We examined 66 malignant TETs. Immunohistochemical evaluation of PD-L1 expression was performed using anti-PD-L1 antibody (SP263). We calculated the tumor cell positive rate (Total Proportion Score: TPS) of PD-L1 expression. The discrimination of the tumor region was confirmed by immunostaining with anti-pan-cytokeratin antibody (AE1AE3). PD-L1 expression was examined for each type of histological classification of TETs. We classified a High TPS group (H group) and Low TPS group (L group) using a TPS cut-off value of 25% and examined the correlation with clinical background and prognosis. We classified Type B2, B3, and thymic carcinomas into a high-malignancy group. PD-L1 expression was also digitally analyzed based on Whole Slides Imagings (WSI) for objective analysis as Digital TPS.

      4c3880bb027f159e801041b1021e88e8 Result

      We identified WHO histological types (Type A/AB/B1/B2/B3/metaplastic tumor/thymic carcinomas = 8/19/5/15/6/2/11). In Type A, PD-L1 expression was low in most cases and the median of TPS was 22%. In Type AB, Type A and B regions showed low and high TPS, respectively, and the median was 23%. In Type B1, TPS was low in most cases and the median was 26%. In Type B2, TPS was higher than that in Type B1, and the median was 69%. In Type B3, TPS was high (>50%) in all cases and the median was 86%. The PD-L1 expression of thymic carcinomas ranged from low to high and the median was 28%. Metaplastic tumors showed scanty PD-L1 expression. The High PD-L1 group showed more advanced disease stages according to the Masaoka stage and TMN classification, and the TPS of Type B2 and B3 was significantly higher than that of Type A, AB and B1. The disease-free survival rate was significantly lower in the H group than that in the L group. When we examined the prognosis in high-malignancy group, there were no significant differences in the disease-freel and overall survival rates by TPS. Based on measurements using WSI, Digital TPS correlated with visual TPS (correlation coefficient=0.85,pvalue<0.001).

      8eea62084ca7e541d918e823422bd82e Conclusion

      TETs had the characteristic features of the PD-L1 expression according to histological types. Type B2 and B3 thymomas was higher PD-L1 expression than the other types of TETs.


      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.